The FLIP Pathology Consortium: Pierre Bedossa, Assistance Publique-Hôpitaux de Paris, hôpital Beaujon, University Paris-Diderot, Paris, France. Alastair D. Burt, School of Medicine, University of Adelaide, Adelaide, Australia. Annette S.H. Gouw, Dept. of Pathology & Medical Biology, University Medical Center Groningen, Groningen, The Netherlands. Carolin Lackner, Institute of Pathology, Medical University of Graz, Graz, Austria. Peter Schirmacher, Institut für Pathologie, Universitätsklinikum Heidelberg, Heidelberg, Germany. Luigi Terracciano, Institute of Pathology, University Hospital, Basel, Switzerland. D. Tiniakos, Medical School, National and Kapodistrian University of Athens, Greece and Medical School, Newcastle University, Newcastle-upon-Tyne, United Kingdom. J. Brain, Medical School, Newcastle University, Newcastle-upon-Tyne, United Kingdom. Yvonne Bury, Royal Victoria Infirmary, Hospitals Foundation Trust, Newcastle-upon-Tyne, United Kingdom. Daniela Cabibi, University of Palermo, Palermo, Italy. Frederic Charlotte, Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie, Paris, France. Ezio David, University of Torino, Ospedale Molinette, Torino, Italy. Luisa Losi, Modena University Hospital, Modena, Italy. Matteo Montani, Institute of Pathology, University of Bern, CH-3010 Bern, Switzerland. María Jesús Pareja, Hospital Universitario de Valme, Sevilla, Spain. Dominique Wendum, Assistance publique-hôpitaux de Paris, Hôpital St Antoine Université Pierre et Marie Curie. Fritz Wrba, Medical University of Vienna, Vienna, Austria. Marianne Ziol, Assistance Publique-Hôpitaux de Paris, Hôpital jean Verdier, Université Paris 13, Bobigny, France. Vlad Ratziu, Assistance Publique Hôpitaux de Paris, Hôpital Pitié Salpêtrière, Université Pierre et Marie Curie, Paris, France.
Steatohepatitis/Metabolic Liver Disease
Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease
Article first published online: 26 JUN 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 60, Issue 2, pages 565–575, August 2014
How to Cite
Bedossa, P. and the FLIP Pathology Consortium (2014), Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology, 60: 565–575. doi: 10.1002/hep.27173
Potential conflict of interest: Nothing to report.
- Issue published online: 22 JUL 2014
- Article first published online: 26 JUN 2014
- Accepted manuscript online: 19 APR 2014 12:40AM EST
- Manuscript Accepted: 11 APR 2014
- Manuscript Revised: 24 MAR 2014
- Manuscript Received: 17 NOV 2013
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- If your institution does not currently subscribe to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.